Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda
| Autor: | Lynnette K Tumwine, Brunangelo Falini, Stefano Pileri, Emmanuel Othieno, Pier Paolo Piccaluga, Wilson Byarugaba, Simona Righi, Henry Wabinga, Cristina Campidelli, Claudio Agostinelli |
|---|---|
| Přispěvatelé: | Tumwine LK, Agostinelli C, Campidelli C, Othieno E, Wabinga H, Righi S, Falini Brunangelo, Piccaluga PP, Byarugaba W, Pileri SA. |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Histology CD30 Pathology and Forensic Medicine immune system diseases Internal medicine hemic and lymphatic diseases Research article Burkitt Lymphoma Herpesvirus 4 Human lymphoma BL medicine lcsh:Pathology B cell CD20 biology business.industry medicine.disease Lymphoma medicine.anatomical_structure linfoma non hodgkin ematologia B-Cell Non-Hodgkin Lymphoma biology.protein Mantle cell lymphoma CD5 business Diffuse large B-cell lymphoma lcsh:RB1-214 |
| Zdroj: | BMC Clinical Pathology BMC Clinical Pathology, Vol 9, Iss 1, p 11 (2009) |
| Popis: | Background Non Hodgkin lymphomas are the most common lymphomas in Uganda. Recent studies from developed countries have shown differences in survival for the different immunophenotypes. Such studies are lacking in Africa where diagnosis is largely dependent on morphology alone. We report immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients in Kampala, Uganda. Methods Non Hodgkin lymphoma tissue blocks from the archives of the Department of Pathology, Makerere University College of Health Sciences, Kampala, Uganda, from 1991-2000, were sub typed using haematoxylin and eosin, Giemsa as well as immunohistochemistry. Using tissue micro array, 119 biopsies were subjected to: CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a, CD138, Bcl-6, Bcl-2, IRTA-1, MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, and Ki-67/Mib1. Case notes were retrieved for: disease stage, chemotherapy courses received and retrospective follow up was done for survival. Results Non Hodgkin B cell lymphomas comprised of Burkitt lymphoma [BL] (95/119) diffuse large B cell lymphoma (19/119), mantle cell lymphoma (4/119) and precursor B lymphoblastic lymphoma (1/119). For Burkitt lymphoma, good prognosis was associated with receiving chemotherapy, female gender and CD30 positivity. Only receiving chemotherapy remained significant after Cox regression analysis. Diffuse large B cell lymphomas with activated germinal centre B cell (GCB) pattern (CD10+/-, BCL-6+/-, MUM+/-, CD138+/-) had better survival (98.4 months; 95% CI 89.5 -107.3) than the others (57.3 months; 95% CI 35.5 - 79.0) p = 0.027 (log rank test). Conclusions Activated GCB diffuse large B cell lymphoma had a better prognosis than the others. For Burkitt lymphoma, not receiving chemotherapy carried a poor prognosis. Availability of chemotherapy in this resource limited setting is critical for survival of lymphoma patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|